Captodiamine Sigma-1 Agonist BDNF Hypothalamus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective cure for Prader-Willi Syndrome, and existing treatments only provide partial relief, with a need for improved therapies to manage its diverse symptoms including obesity, cognitive impairment, and behavioral issues.
Innovation Solution
Administration of a pharmaceutical composition containing captodiamine or its pharmaceutically acceptable salt, which acts as a sigma-1 receptor agonist and 5-HT2C antagonist, increasing brain-derived neurotrophic factor (BDNF) levels in the hypothalamus to address symptoms such as hyperphagia, obesity, and cognitive impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If growth hormone, exercise, and dietary supervision are used to treat PWS, then muscle mass and body composition improve, but weight control and appetite management remain insufficient
Solution Approach 1:
Captodiamine acts as a pharmacological intermediary that targets the underlying neurobiological mechanisms of PWS. The compound increases hypothalamic BDNF expression and modulates neurotransmitter systems (dopamine, serotonin, norepinephrine), thereby addressing the root cause of hyperphagia and weight control difficulties rather than merely managing symptoms through diet and exercise supervision
Solution Approach 2:
The treatment fundamentally changes key physiological parameters in PWS patients by increasing BDNF levels in the hypothalamus and modulating neurotransmitter activity. These parameter changes lead to improved appetite regulation, reduced hyperphagia, and better weight control, complementing the physical benefits of growth hormone therapy
2Reliability
If conventional treatments are applied, then some symptoms are managed, but no effective cure exists and specialized care is needed throughout life
Solution Approach 1:
Captodiamine serves as a disease-modifying intermediary that addresses the core neurobiological deficits in PWS. By targeting BDNF expression and neurotransmitter systems, it provides a more comprehensive and potentially curative treatment approach rather than requiring lifelong multidisciplinary symptom management
3Object-affected harmful factors
If BDNF is selectively up-regulated in the hypothalamus, then appetite and weight gain are inhibited, but the mechanism requires precise targeting to avoid side effects
Solution Approach 1:
Captodiamine acts as a systemic pharmacological intermediary that achieves selective hypothalamic BDNF up-regulation through its pharmacokinetic properties and mechanism of action. The compound's ability to cross the blood-brain barrier and selectively affect hypothalamic neurotransmitter systems allows for targeted appetite regulation without requiring direct hypothalamic intervention
Solution Approach 2:
The treatment changes the BDNF concentration parameter specifically in the hypothalamus through pharmacological induction. This parameter change in BDNF levels leads to downstream effects on appetite regulation and weight control, achieving the desired therapeutic effect with systemic administration rather than localized intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Captodiamine treatment provides significant improvement in symptoms like hyperphagia, obesity, cognitive impairment, and behavioral issues by increasing hypothalamic BDNF expression, offering a potential therapeutic benefit for Prader-Willi Syndrome patients.
Implementation Method 1
acts as a sigma-1 receptor agonist and 5-HT2C antagonist, increasing brain-derived neurotrophic factor (BDNF) levels in the hypothalamus
Implementation Method 2
acts as a sigma-1 receptor agonist and 5-HT2C antagonist, increasing brain-derived neurotrophic factor (BDNF) levels in the hypothalamus
Data Source
AI summary
Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I,or a pharmaceutically acceptable salt thereof, wherein R, R′, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.